The candidate previously demonstrated promising weight loss outcomes in Phase 2 trials, and its progression into late-stage testing underscores the competitive momentum building in this high-growth therapeutic category In January 2024, Zealand Pharma and Boehringer Ingelheim announced positive Phase 2 results for BI 456906, a long-acting GLP-1/glucagon dual agonist, in obese individuals
Frequently Asked Questions Glutathione is a powerful antioxidant that helps protect your cells from damage caused by free radicals and oxidative stress
My appetite is way more controlled on Retatrutide, I'm not constantly thinking about food, this pen is amazing for me personally
Patients described feeling less hungry, which results in eating less and provides a conducive environment to lose fat
A 503A pharmacy prepares customized medications for individual patients based on valid prescriptions from licensed healthcare providers
Names like Diapason GLP-1 and Lercea GLP-1 are everywhere, claiming to be the "natural alternative" to prescription medications